Polaryx Therapeutics, Inc. Common Stock carries no debt; cash flow comfortably covers obligations.

Polaryx Therapeutics, Inc. Common Stock's free cash flow has decreased 53.28% from $-2.57M last year to $-3.94M, signaling decreasing performance

Polaryx Therapeutics, Inc. Common Stock's debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

Polaryx Therapeutics, Inc. Common Stock has insufficient data to evaluate this check.

Polaryx Therapeutics, Inc. Common Stock has negative EBITDA, making leverage ratio unreliable

Polaryx Therapeutics, Inc. Common Stock earns at least as much interest as it pays. Interest obligations are fully covered.

Polaryx Therapeutics, Inc. Common Stock has insufficient data to evaluate this check.

Polaryx Therapeutics, Inc. Common Stock's short-term assets of $5.17M exceed its short-term liabilities of $605.00K

Polaryx Therapeutics, Inc. Common Stock's return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Polaryx Therapeutics, Inc. Common Stock's return on equity of -166.07%, is lower than 15.00%, indicating bad performance

Polaryx Therapeutics, Inc. Common Stock's operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Polaryx Therapeutics, Inc. Common Stock had positive net income in only 0.00 out of 5 years, indicating unstable earnings

Polaryx Therapeutics, Inc. Common Stock has negative free cash flow, indicating the company is burning cash rather than generating it

Polaryx Therapeutics, Inc. Common Stock has negative free cash flow, indicating cash burn

Polaryx Therapeutics, Inc. Common Stock's yearly earnings has increased -70.40% since last year from $-30.36M to $-8.98M, signaling increasing performance

Polaryx Therapeutics, Inc. Common Stock's yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -189.99% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Polaryx Therapeutics, Inc. Common Stock has insufficient revenue history to calculate 3-year revenue CAGR.

Polaryx Therapeutics, Inc. Common Stock had revenue growth in only 2.00 out of 5 years, indicating inconsistent revenue performance

Polaryx Therapeutics, Inc. Common Stock had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity

Polaryx Therapeutics, Inc. Common Stock has insufficient data to evaluate this check.

Polaryx Therapeutics, Inc. Common Stock has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Polaryx Therapeutics, Inc. Common Stock is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Polaryx Therapeutics, Inc. Common Stock has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Polaryx Therapeutics, Inc. Common Stock has insufficient data to evaluate this check.

Polaryx Therapeutics, Inc. Common Stock has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Polaryx Therapeutics, Inc. Common Stock has a price-to-book ratio of 45.55x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Polaryx Therapeutics, Inc. Common Stock has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue